Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6609 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-09-26 (biospace.com)
Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
– The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritis –
Read more
2024-07-22 (ciolook.com)
Nishtha Jain: Bridging Technology and Healthcare for Better Patient Care
Innovating Healthcare Solutions!
Read more
2023-11-25 (nature.com)
An explainable machine learning-based phenomapping strategy for adaptive predictive enrichment in randomized clinical trials - npj Digital Medicine
Randomized clinical trials (RCT) represent the cornerstone of evidence-based medicine but are resource-intensive. We propose and evaluate a machine learning (ML) strategy of adaptive predictive enrichment through computational trial phenomaps to optimize RCT enrollment. In simulated group sequential
Read more
2023-08-05 (pharmiweb.com)
FDA Approves ZURZUVAETM (zuranolone), the First and Only Oral Treatment Approved for Women with Postp
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45Mental health conditions are the leading cause of maternal mortality...
Read more
2023-08-05 (globenewswire.com)
FDA Approves ZURZUVAETM (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved...
Read more
2022-04-29 (smanewstoday.com)
#AAN2022 - In SMA Children, Spinraza Showing Safety After Zolgensma
Early safety findings were good in 9 children, all with a suboptimal response to Zolgensma, being treated with Spinraza in the RESPOND trial.
Read more
2017-10-24 (foxbusiness.com)
Health Care Down After Earnings - Health Care Roundup
Shares of health-care companies fell amid mixed earnings reports. Shares of Biogen slid after analysts noted that U.S. quarterly sales of its Spinraza therapy for spinal muscular atrophy were flat from a year earlier. Alexion ticked up after the Food and Drug Administration approved a wider
Read more
2016-09-07 (pharmatimes.com)
UK launch for Biogen’s biosimilar infliximab
Biogen has launched Flixabi - a biosimilar of Johnson & Johnson's blockbuster infliximab - across the UK for use in a range of chronic inflammatory conditions.
Read more
(devdiscourse.com)
Health News Roundup: Cough syrup deaths overseas prompt US crackdown on toxic testing; Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen and more
The Food and Drug Administration has reprimanded at least 28 companies this year, saying they failed to prove sufficient testing of ingredients used in over-the-counter drugs and consumer products for the toxins ethylene glycol( EG) and diethylene glycol( DEG), according to a Reuters analysis of
Read more